Abstract
Regorafenib is a potent multitargeted tyrosine kinase inhibitor blocking several signalling pathways (kinases of VEGFR family, PDGFR kinase, oncogenic mutant kinases KIT, RET, BRAF and p38 MAP). This broad mechanism of action is favourable mainly in heavily pretreated patients, where, during several lines of antitumor treatments, activation of pathological signalling pathways occurs.
Considering number of indications, regorafenib became one of the biological drugs with the broadest use in oncology. Currently in the Czech Republic, regorafenib is indicated for treatment of advanced gastrointestinal stromal tumor, advanced colorectal cancer and advanced hepatocellular carcinoma.